VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Comparison

ALVAC-BTV-VP2/VP5 rCPV-BTV-Cpox SG33-VP2/5
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004726
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: A recombinant canarypox virus vector was used to co-express genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus (Boone et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004788
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: BTV recombinant capripoxviruses (BTV-Cpox) individually expressing four different genes encoding two capsid proteins (VP2 and VP7) and two non-structural proteins (NS1, NS3) of BTV serotype 2 (BTV-2) (Perrin et al., 2007).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004706
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Sheep
  • Preparation: MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012)
  • Immunization Route: Other
Host Response Host Response Host Response

Sheep Response

  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The field strain of BTV-17 was used for challenging (Boone et al., 2007).
  • Efficacy: The sheep vaccinated with the recombinant canarypox virus vectored vaccine were resistant to challenge with a field strain of BTV-17 (Boone et al., 2007).

Sheep Response

  • Vaccination Protocol: Sheep were immunized with BTV recombinant capripoxviruses (BTV-Cpox) (Perrin et al., 2007).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The sheep were challenged with a virulent strain of BTV-2 (Perrin et al., 2007).
  • Efficacy: Sheep challenged 3 weeks after BTV-Cpox vaccination exhibited partial protection (Perrin et al., 2007).

Sheep Response

  • Vaccination Protocol: Sheep were injected twice with an MYXV expressing the immunodominant VP2 protein (SG33-VP2) (Top et al., 2012).
  • Vaccine Immune Response Type: VO_0000287
  • Immune Response: The SG33-VP2 vector promoted the production of neutralising antibodies (Maclachlan et al., 2009).
  • Efficacy: The SG33-VP2 vector expressing VP2 partially protected sheep against disease after challenge with a highly virulent strain of serotype-8 bluetongue virus (BTV-8) (Top et al., 2012).
References References References
Boone et al., 2007: Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, Monaco F, Savini G, Gardner IA, Maclachlan NJ. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine. 2007; 25(4); 672-678. [PubMed: 17059856].
Perrin et al., 2007: Perrin A, Albina E, Bréard E, Sailleau C, Promé S, Grillet C, Kwiatek O, Russo P, Thiéry R, Zientara S, Cêtre-Sossah C. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine. 2007; 25(37-38); 6774-6783. [PubMed: 17669563].
Maclachlan et al., 2009: Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. Journal of comparative pathology. 2009; 141(1); 1-16. [PubMed: 19476953].
Top et al., 2012: Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli S, Meyer G. Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus. Vaccine. 2012; 30(9); 1609-1616. [PubMed: 22244980].